GlaxoSmithKline (GSK) is a global pharmaceutical company headquartered in London. It has a portfolio of products for major disease areas such as asthma, cancer, infections and mental health. GSK was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. It has operations in over 120 countries and sells products in over 150 countries. Its top competitors include Johnson & Johnson, Pfizer, Merck and AstraZeneca.

1. Glaxo Smith Kline

2. GSK’S Introduction GlaxoSmithKline often abbreviated to GSK, is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom.

3. GSK’S Introduction It is world’s third largest pharmaceutical company measured by revenues ( after Johnson and Johnson and Pfizer. It has a portfolio of products for major disease areas including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions.

6. Chairman: Sir Christopher Gent Chief Executive Officer: Andrew Witty

7. GSK’s Mission GSK MISSION GROW MISSION SIMPLYFY DELIVER

11. PRESCRIPTION MEDICINES

12. ALLI-WEIGHT LOSS DRUG

13. AVANDIA-DIABETIS CONTROL

14. ROTAVIRUS VACCINE ROTARIX

15. VACCINE FOR MEASLES

16. CONSUMER HEALTHCARE PRODUCTS

17. CONSUMER HEALTHCARE PRODUCTS

18. Two other companies Stiefel, a GSK company— A Global Leader in Dermatology ViiV Healthcare — a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people

19. STIEFEL-A GSK COMPANY

20. VIIV- HEALTHCARE COMPANY

21. Turnover ( in billion pounds) 2009 28.4 2008 24.4 2007 22.7 2006 23.2 2005 21.7

22. World market by geographic region value(billion pounds) % of total USA 187 40 Europe 131 28 France 25 5 Germany 24 5 Italy 16 3 UK 12 3 Rest of World 150 32 Emerging markets 66 14 Asia Pacific 20 4 Japan 50 11 Canada 11 2

23. Regional analysis (2009) (2008) cer% pnd% USA 9,180 8,894 (13) 3 Europe 7,681 6,483 9 18 Emerging Markets 2,973 2,290 20 30 Asia Pacific/Japan 2,700 1,918 16 41 Other trading‡ 1,180 796 31 48 23,714 20,381 2 16

24. CER% represents growth at constant exchange rates. Pound % growth at actual exchange rates.

25. Consumer Healthcare turnover(million pounds) (2009) (2008) cer% pound % Over the counter 2,319 1935 8 20 Medicines Oral healthcare 1484 1240 7 20 Nutritional healthcare 851 796 3 7

26. Sales Trend

28. JAPAN

29. GERMANY

30. SWITZERLAND

32. JOHNSON &JOHNSON

33. ABBOT LABORATARIES

34. MERCK &CO.

35. ELI LILLY

36. BRISTOL-MYERS SQUIBB

37. COMPETITORS IN JAPAN NAME OF THE COUNTRY TAKEDAPHARMACEUTICAL. ASTELLAS PHARMA DAIICHI SANKYO 9 EISAI CHUGAI PHARMACEUTICAL . TOTAL REVENUE (IN USD BILLIONS) 15.6 10.7 9 5.5 2.0

38. TAKEDA PHARMACEUTICALS

39. ASTELLAS PHARMA

40. DAIICHI SANKYO

41. EISAI

42. CHUGAI PHARMACEUTICALS

43. COMPETITORS IN GERMANY NAME OF THE COUNTRY BAYER BOEHRINGER INGELHEIM MERCK kGaA TOTAL REVENUE (IN USD BILLIONS) 22.3 16.9 5.17

44. BAYER

45. BOEHRINGER INGELHEIM

46. MERCK KGAA

47. COMPETITORS IN SWITZERLAND NAME OF THE COUNTRY HOFFMAN LA ROCHE NOVARTIS NYCOMED TOTAL REVENUE (IN USD BILLIONS) 47.35 44.27 4.26

48. HOFFMAN LA ROCHE

49. NOVARTIS

50. NYCOMED

51. COMPETITORS IN UK NAMEOF THE COMPANY TOTAL REVENUE (IN USD BILLIONS) 45.83 32.81 GlaxoSmithKline AstraZeneca

52. ASTRA ZENECA

53. SUBMITTED BY: ISHDEEP SINGH M100700019